During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Nuvation Bio, listed via SPAC in 2021, and acquired AnHeart Therapeutics last year, gaining taletrectinib, a promising ROS1 inhibitor indicated for non-small cell lung cancer. The FDA has accepted ...

“This EAP reflects our unwavering dedication to patients with ROS1-positive NSCLC,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “We are committed ...

The program targets individuals with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have exhausted other treatment options. The EAP, authorized by the U.S ...

Nuvation Bio (NYSE:NUVB) said the FDA has accepted its application with priority review for its therapy taletrectinib in the treatment of advanced ROS1+ non-small cell lung cancer.

On the 5th, HLB PANAGENE said that the "PANAMutyper™ ROS1" has received item approval from the Ministry of Food and Drug Safety as a companion diagnostic product for Pfizer's lung cancer ...

Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today reported financial results for the fourth quarter and full year ended ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...